Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone antibiotic presented as an intravenous solution for intravenous use. Approved in the European Union, it treats complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, as well as infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) in adult patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with full regulatory documentation and quality assurance.

Linezolid is an oxazolidinone antibiotic used to treat serious bacterial infections.

Complicated skin and soft tissue infections: reduces bacterial load and promotes healing in infections caused by susceptible Gram‑positive organisms. Community‑acquired and nosocomial pneumonia: improves respiratory outcomes by targeting resistant Streptococcus pneumoniae and Staphylococcus aureus. Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides bacteriostatic activity against MRSA strains in various infection sites. Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative treatment option for VRE‑related infections.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial discomfort. - Vomiting: occasional stomach upset with emesis. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects: - Myelosuppression: severe decrease in blood cell production. - Peripheral neuropathy: sensory nerve damage with prolonged use. - Lactic acidosis: rare metabolic disturbance that can be life‑threatening. - Serotonin syndrome: risk when combined with serotonergic agents.

When prescribing Linezolid, clinicians should consider several safety and handling precautions.

- Renal impairment: adjust monitoring as drug is primarily excreted unchanged. - Hepatic dysfunction: observe liver function tests during therapy. - Hematologic monitoring: check complete blood count for thrombocytopenia or anemia. - Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. - Prolonged therapy: limit duration to reduce risk of peripheral neuropathy. - Store at ambient temperature: keep in original container, protect from light and moisture.

Linezolid interacts with several medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis. - Rifampicin: reduces linezolid plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Ethanol: may increase risk of disulfiram‑like reaction. - Anticonvulsants (e.g., carbamazepine, phenytoin): may lower linezolid levels.